Study of WAL0921 in Patients With Glomerular Kidney Diseases

Condition(s) studied

Investigational drug(s) / intervention(s)

WAL0921: Investigational drug WAL0921 Participants receive an intravenous infusion of WAL0921 investigational drug once every 2 weeks for 7 total infusions.

Placebo: Placebo product Participants receive an intravenous infusion of placebo once every 2 weeks for 7 total infusions.

Study summary

This is an adaptive prospective, multi-center, randomized, double-blind, placebo-controlled study to evaluate the safety, efficacy, pharmacokinetics, and pharmacodynamics of WAL0921 in subjects with glomerular kidney disease and proteinuria, including diabetic nephropathy and rare glomerular kidney diseases (primary focal segmental glomerulosclerosis \[FSGS\], treatment-resistant minimal change disease \[TR MCD\], primary immunoglobulin A nephropathy \[IgAN\], and primary membranous nephropathy \[PMN\]). Subjects in this study will be randomized to receive the investigational drug WAL0921 or placebo as an intravenous infusion once every 2 weeks for 7 total infusions. All subjects will be followed for 24 weeks after their last infusion.

Eligibility

Primary outcome measure(s)

• Incidence of treatment emergent adverse events — Baseline to Week 36

Trial sites (50)

+ 10 more sites — see the full list on the official registry below.

Other trials for the same condition